2. Academic Validation
  3. Standardized GMP-compliant scalable production of human pancreas organoids

Standardized GMP-compliant scalable production of human pancreas organoids

  • Stem Cell Res Ther. 2020 Mar 4;11(1):94. doi: 10.1186/s13287-020-1585-2.
Marta Dossena 1,  Roberta Piras 1,  Alessandro Cherubini 1,  Mario Barilani 1 2,  Erica Dugnani 3,  Francesca Salanitro 1,  Till Moreth 4,  Francesco Pampaloni 4,  Lorenzo Piemonti 3 5,  Lorenza Lazzari 6
Affiliations

Affiliations

  • 1 Laboratory of Regenerative Medicine - Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.
  • 2 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • 3 IRCCS Ospedale San Raffaele, San Raffaele Diabetes Research Institute, Milan, Italy.
  • 4 Physical Biology Group, Buchmann Institute for Molecular Life Sciences (BMLS), Goethe Universität Frankfurt am Main, Frankfurt am Main, Germany.
  • 5 Vita-Salute San Raffaele University, Milan, Italy.
  • 6 Laboratory of Regenerative Medicine - Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy. lorenza.lazzari@policlinico.mi.it.
PMID: 32127043 DOI: 10.1186/s13287-020-1585-2
Abstract

Background: Organoids are three-dimensional in vitro-grown cell clusters that recapitulate key features of native organs. In regenerative medicine, Organoid technology represents a promising approach for the replacement of severely damaged organs, such as the pancreas in patients with type 1 diabetes. Isolation human pancreas organoids (hPOs) in chemically defined serum-free culture media would be a major milestone for this approach.

Methods: Starting from discarded pancreatic tissues, we developed a large-scale process for obtaining clinically relevant quantities of undifferentiated organoids, obviating enzymatic digestion and operator-dependent pancreatic ducts picking steps. hPO identity was characterized by molecular and flow cytometry analysis.

Results: This work demonstrates that it is possible to obtain a large-scale production of organoids. We introduced some innovations in the isolation, expansion, and freezing of hPOs from five donors. First of all, the choice of the starting material (islet-depleted pancreas) that allows obtaining a high quantity of hPOs at low passages. On the Other hand, we introduced mechanical dissociation and we eliminated the picking step to exclude the operator-depending steps, without affecting the success of the culture (100% success rate). Another important improvement was to replace R-spondin-1 (Rspo1) conditioned medium with Rspo1 recombinant molecule to obtain a well-defined composition of the expansion medium. Finally, we implemented a GMP-compliant freezing protocol. hPOs showed exponential growth with diameter and area that increased three- and eight-fold in 7 days, respectively. Immunophenotypic profile and gene expression analysis revealed that hPOs were composed of ductal (82.33 ± 8.37%), acinar (2.80 ± 1.25%) cells, and pancreatic progenitors (5.81 ± 2.65%).

Conclusion: This work represents a milestone for a GMP-compliance hPO production and, ultimately, their clinical application as a type 1 diabetes therapy.

Figures
Products